格隆汇12月29日丨微创脑科学(02172.HK)宣布，董事会决议设立董事会下设的战略委员会，自2025年12 月29日起生效。董事会决议设立董事会下设的商业化委员会，自2025年12月29日起生效。 ...

战略委员会及商业化委员会成立后，各有关委员会的组成如下，自2025年12月29日起生效：战略委员会 由四名成员组成，包括张劼博士、谢志永先生、李志勇先生及刘安先生，由张劼博士担任主席。商业化 委员会由五名成员组成，包括谢志永先生、王亦群先生、刘旭东先生、李志勇先生及刘安先生，由王亦 群先生担任主席。 公司审核委员会及公司薪酬委员会的组成变动如下，自2025年12月29日起生效：非执行董事兼董事会主 席张劼博士已获委任为薪酬委员会的成员。执行董事谢志永先生不再担任薪酬委员会的成员。独立非执 行董事刘安先生已获委任为审核委员会的成员。独立非执行董事李志勇先生不再担任审核委员会的成 员。 智通财经APP讯，微创脑科学(02172)发布公告，董事会决议设立董事会下设的战略委员会，自2025年12 月29日起生效。 董事会决议设立董事会下设的商业化委员会，自2025年12月29日起生效。 刘安先生已获委任为独立非执行董事，自2025年12月29日起生效。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 MicroPort NeuroScientic Corporation 微創腦科學有限公司 微創腦科學有限公司的董事會（「董事會」）成員載列如下： 張劼博士 （非執行董事兼董事會主席） 謝志永先生 （執行董事） 王亦群先生 （執行董事） 劉旭東先生 （非執行董事） 吳夏女士 （非執行董事） 張海曉博士 （獨立非執行董事） 樊欣先生 （獨立非執行董事） 李志勇先生 （獨立非執行董事） 劉安先生 （獨立非執行董事） 董事會設立五個委員會。下表提供各董事會成員於該等委員會中所擔任的職位。 | | 委員會 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | | | 審核委員會 | 薪酬委員會 | 提名委員會 | 戰略委員會 | 商業化委員會 | | 董事 | | | | | | | | 張劼博士 | | | 成員 | | 主席 | | | 謝志永先 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 MicroPort NeuroScientic Corporation 微創腦科學有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：2172） (1)設立戰略委員會； (2)設立商業化委員會； (3)委任獨立非執行董事； (4)委任戰略委員會及商業化委員會之成員；及 (5)審核委員會及薪酬委員會組成變動 設立戰略委員會 微創腦科學有限公司（「本公司」，連同其附屬公司統稱（「本集團」））董事（「董 事」）會（「董事會」）謹此宣佈，董事會決議設立董事會下設的戰略委員會（「戰 略委員會」），自二零二五年十二月二十九日起生效。設立戰略委員會旨在就本 公司長期發展戰略及重大發展決策進行研究並提出建議。本公司以創新驅動， 持續完善其全面的腦卒中治療解決方案，積極開拓腦科學新邊界，並已於近期 成立混沌腦機研究院。同時，本公司積極推進全球業務佈局，不斷提升品牌的 國際影響力。此次設立 ...

Core Viewpoint - The brain-computer interface (BCI) sector is experiencing significant growth driven by favorable policies, technological advancements, and increased investment interest, as evidenced by the recent surge in stock prices of related companies in both Hong Kong and A-share markets [2][6][7]. Policy Developments - The National Medical Products Administration has included implantable brain-computer interface medical devices in the "Priority Approval List for High-end Medical Devices (2025 Edition)" [2]. - A joint initiative by seven ministries, including the Ministry of Industry and Information Technology, has set phased goals for the BCI industry by 2027 and 2030 [3]. - The "14th Five-Year Plan" emphasizes the BCI sector as a key area for fostering new economic growth [4]. - The National Healthcare Security Administration has introduced new pricing guidelines for invasive BCI procedures, facilitating reimbursement pathways [4]. Technological Advancements - Recent breakthroughs in BCI technology include the first domestically developed fully implanted, wireless BCI product by Brain Tiger Technology, which successfully completed its first clinical trial [5]. - The National Medical Products Administration has approved the world's first invasive BCI product for treating addiction-related mental disorders [5]. - Ongoing clinical trials and collaborations among research institutions and medical units are yielding significant progress in the field [5]. Market Insights - The BCI industry is entering a rapid commercialization phase, supported by policy backing, technological breakthroughs, and increased capital influx [5][6]. - The market for BCI is projected to be a nearly $10 billion opportunity globally, with domestic companies making strides in flexible electrodes and real-time Chinese language decoding [7]. - Investment interest in the BCI sector is rising, particularly in rehabilitation applications and non-invasive BCI technologies, as companies strategically position themselves for future growth [6][7].

Group 1 - The Hong Kong stock market's brain-computer interface sector experienced a collective surge, with notable increases in stock prices for several companies [1] - Heartway Medical-B saw a rise of over 12%, while Brain Dynamics-B and Nanjing Panda Electronics both increased by over 7% [1] - The Fifth Frontier Brain Science and Industry Conference and the 2025 Shenzhen Brain-Computer Interface Expo commenced on December 28, marking the official launch of the "Guangdong-Hong Kong-Macau Greater Bay Area Brain Science and Central Nervous System Disease AI Innovation Alliance" [1] Group 2 - Heartway Medical-B's latest price is 54.000, with a total market capitalization of 2.069 billion and a year-to-date increase of 146.01% [2] - Brain Dynamics-B's latest price is 6.790, with a total market capitalization of 8.598 billion and a year-to-date increase of 110.87% [2] - Nanjing Panda Electronics' latest price is 4.650, with a total market capitalization of 4.249 billion and a year-to-date increase of 35.57% [2] - Brainhole Technology's latest price is 0.230, with a total market capitalization of 0.0184 billion and a year-to-date increase of 1.77% [2] - Microneuroscience's latest price is 11.000, with a total market capitalization of 6.336 billion and a year-to-date increase of 30.18% [2]

Group 1 - The core point of the article highlights that on December 22, shareholders of MicroPort NeuroTech (02172) transferred shares from CITIC Securities Brokerage Hong Kong to Guotai Junan (Hong Kong), with a total market value of HKD 315 million, representing 5.01% of the company [1] - MicroPort NeuroTech announced that on November 20, 2025, the company resolved to grant stock options to Dr. Will Zhang, the Senior Director of Brain-Machine Interface Technology R&D and Chief Researcher at the Chaos Brain-Machine Research Institute, under the stock plan adopted on July 12, 2023, allowing for the subscription of up to 500,000 shares of the company's common stock at a par value of USD 0.00002 per share, pending acceptance by the grantee [1]

Core Viewpoint - The recent transfer of shares in Micron Brain Science (02172) indicates a strategic shift in shareholder engagement and potential future developments in the company's stock performance [1] Group 1: Shareholder Activity - On December 22, shareholders of Micron Brain Science transferred shares from CITIC Securities Brokerage Hong Kong to Guotai Junan (Hong Kong), with a total market value of HKD 315 million, representing 5.01% of the company [1] Group 2: Stock Options Grant - Micron Brain Science announced that on November 20, 2025, the company resolved to grant stock options to Dr. Will Zhang, the Senior Director of Brain-Computer Interface Technology R&D and Chief Researcher at the Chaos Brain-Computer Research Institute, under the stock plan adopted on July 12, 2023, allowing for the subscription of up to 500,000 shares of the company's common stock at a par value of USD 0.00002 per share, pending acceptance by the grantee [1]

Core Viewpoint - The brain-computer interface (BCI) sector is experiencing a significant surge in stock prices, driven by recent developments in regulatory support and technological advancements [1]. Group 1: Stock Performance - Nanjing Panda (00553) increased by 4.16%, reaching HKD 4.51 [1] - MicroPort NeuroTech (02172) rose by 4.24%, trading at HKD 10.83 [1] - BrainCo (06681) saw a 2.58% increase, priced at HKD 5.96 [1] Group 2: Regulatory Developments - The National Medical Products Administration held a meeting on December 18 to advance BCI medical device initiatives [1] - The meeting emphasized the strategic importance of BCI in future industry development and the need for safety and effectiveness as primary considerations [1] - It called for innovative regulatory methods, the establishment of standard systems, and enhanced technical guidance [1] Group 3: Industry Outlook - According to Guotai Junan, the BCI industry is poised for significant growth due to technological breakthroughs, policy support, and capital investment [1] - There is an anticipated release of demand in downstream markets such as healthcare and consumer goods, indicating a promising market outlook [1]

Core Viewpoint - The Hong Kong stock market is experiencing a surge in brain-computer interface concept stocks, indicating growing investor interest in this sector [1] Group 1: Stock Performance - Nanjing Panda (00553.HK) increased by 4.16%, reaching HKD 4.51 [1] - Weikang Brain Science (02172.HK) rose by 4.24%, trading at HKD 10.83 [1] - Brain Motion Aurora-B (06681.HK) saw a gain of 2.58%, priced at HKD 5.96 [1]